L01XX35 • anagrelide • Antineoplastic and immunomodulating agents | Other antineoplastic agents
Anagrelide is a medication used for the treatment of essential thrombocythemia, a hematological condition characterized by an excessive number of platelets in the blood. This condition can increase the risk of blood clot formation, leading to complications such as strokes or heart attacks. Anagrelide works by inhibiting the maturation of megakaryocytes, the precursors of platelets, thereby reducing the platelet count in the blood.
Anagrelide is administered orally, usually two to four times daily, with the dosage adjusted based on the patient's response and platelet levels.
Common side effects include headaches, dizziness, nausea, diarrhea, and palpitations. In rare cases, severe adverse reactions such as heart failure or liver function impairment may occur.
Patients taking anagrelide should undergo regular monitoring for platelet counts and signs of adverse reactions. Additionally, the medication may interact with other anticoagulant or antiplatelet therapies, requiring caution. Anagrelide is an effective option for managing essential thrombocythemia, helping to reduce the risk of thrombotic complications.
Substance: anagrelide
Date of last drug list: 01-08-2019
Commercial code: W65867002
Concentration: 0.5mg
Pharmaceutical form: tablets
Quantity: 100
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: QPHARMA AB - SUEDIA
Holder: NORDIC GROUP B.V. - OLANDA
Number: 11556/2019/02
Shelf life: 3 years